CASP3 and glioblastoma: We observed a trend for increased cleaved caspase 3 (Extended Data Fig. 7b) and reduced tumor cell size (Extended Data Fig. 7c) after treatment with lomustine (CCNU), JNJ10198400 and cyclosporine-treated high-neural glioblastoma cells, whereas talazoparib showed a trend for greater sensitivity in low-neural glioblastoma cells; however, none of these compounds reached statistical significance (Extended Data Fig. 7d).